<DOC>
	<DOCNO>NCT00854360</DOCNO>
	<brief_summary>This phase 2 , randomize , double-blind , placebo-controlled , parallel-group , 2-week , multi-center , dose-range-finding study male female patient ( 12 year old ) SAR .</brief_summary>
	<brief_title>Study Assess Efficacy Safety BDP HFA Nasal Aerosol Patients 12 Years Older With SAR</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Key Male female patient 12 year age old , Screening Visit ( SV ) . General good health , free concomitant condition treatment could interfere study conduct , influence interpretation study observations/results , put patient increase risk study . A history SAR relevant seasonal allergen ( tree/grass pollen ) minimum two year immediately precede study Screening Visit ( SV ) . The SAR must sufficient severity require treatment ( either continuous intermittent ) past investigator 's judgment expect exposed allergen require treatment throughout entire study period . A demonstrated sensitivity relevant tree/grass pollen know produce SAR standard skin prick test . A positive test define wheal diameter least 3 mm large control wheal skin prick test . Documentation positive result within 12 month prior Screening Visit ( SV ) acceptable . Other criterion apply Key Participation investigational drug study within 30 day precede Screening Visit ( SV ) plan participation another investigational drug study time study . History physical finding nasal pathology , include nasal polyp clinically significant respiratory tract malformation , recent nasal biopsy , nasal trauma surgery , atrophic rhinitis , rhinitis medicamentosa ( within last 60 day prior SV ) . History respiratory infection disorder [ include , limited bronchitis , pneumonia , chronic sinusitis , influenza , severe acute respiratory syndrome ( SARS ) ] within 14 day precede Screening Visit ( SV ) , development respiratory infection Runin Period . Use prohibit concomitant medication within prescribe ( per protocol ) time since last dosing period prior Screening Visit ( SV ) and/or plan use entire treatment duration . Other criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Seasonal Allergic Rhinitis</keyword>
	<keyword>Hayfever</keyword>
</DOC>